NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Fulcrum Therapeutics, Inc. (FULC) Stock Analysis

Fulcrum Therapeutics, Inc. (FULC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

FULC

$3.70

−$0.02 (−0.54%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FULC with… →

FULC Key Statistics

As of Oct 21, 2026
Trading
Open
$3.72
Previous Close
$3.72
Day's Range
3.70–3.75
52-Week Range
2.83–15.74
Volume
923.78K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.63
Valuation
Market Cap
$282.61M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.21
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$74.88M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
76.38M
1-Year Return
−61.86%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
1.52M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, FULC closed at $3.70, −61.86% over 1 year.

Fulcrum Therapeutics, Inc. (FULC) has a market capitalization of $282.61M.

In fiscal 2025, FULC reported revenue of $0.00.

FULC Stock Return by Calendar Year

Fulcrum Therapeutics, Inc. (FULC) return since Jul 2019: what $10,000 became

1 year
$10,000 $3,814
−61.86%
5 years
$10,000 $1,516
−84.84%
Since Jul 2019
$10,000 $2,741
−72.59%

If you had invested $10,000 in Fulcrum Therapeutics, Inc. (FULC) at the close on July 18, 2019, the earliest close on record here, it would have been worth $2,741 at the close on October 21, 2026: −72.59% in total, −16.33% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−67.29%
2025+140.64%
2024−30.37%
2023−7.28%
2022−58.85%
2021+51.07%
2020−29.63%
2019 (partial year)+23.26%

As of October 21, 2026.

FULC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$74.88M—
2024$80.00M−$9.73M−12.2%
2023$2.81M−$97.34M−3,470.1%
2022$6.34M−$109.87M−1,732.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$84.77M−$74.88M—
2024$80.00M—−$19.83M−$9.73M−12.2%
2023$2.81M—−$110.66M−$97.34M−3,470.1%
2022$6.34M—−$112.13M−$109.87M−1,732.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Fulcrum Therapeutics, Inc. (FULC) is capitalised at $282.61M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 9 employees.

Over the past 52 weeks the price has ranged from $2.83 to $15.74. The most recent close on file for FULC is $3.70, dated October 21, 2026. That is −$0.02 (−0.54%) against the previous close. The latest close sits 30.74% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. That is −100.00% against the prior fiscal year, when revenue was $80.00M. The same year closed with a net loss of $74.88M. Trailing earnings per share are −1.21.

Across the 4 fiscal years on file, revenue moves from $6.34M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 2.63. Daily returns over the trailing 7 years annualize to a volatility of 109.71%. The trailing one-year total return is −61.86%. Measured over 5 years, that is −31.43% a year compounded.

Growth & Income

The record shows no dividend for FULC.

The strongest complete calendar year on file is 2025 at +140.64%; the weakest is 2022 at −58.85%. Of the 6 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −67.29% year to date.

Peer Comparison

Fulcrum Therapeutics, Inc. (FULC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fulcrum Therapeutics, Inc. FULC $282.61M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Fulcrum Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Visit website →